.jpg)
STAT Plus: Blueprint Medicines wins U.S. approval for genetically targeted lung cancer drug
The Food and Drug Administration on Friday approved a new drug from Blueprint Medicines for patients with lung cancer driven by a rare gene mutation.
The Blueprint drug, a once-daily pill called Gavreto, is the second treatment approved to treat lung tumors that harbor alterations to a gene called RET. In May, Eli Lilly won approval for a similar drug called Retevmo.
